Keywords: forest, labs, completes, alzheimer, drug, trials, laboratories

Forest Labs Completes Alzheimer Drug Trials

Article | 19 August 1996

Forest Laboratories has completed its Phase III clinical trials with Synapton (sustained-release physostigmine), an acetylcholinesterase inhibitor for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Forest Laboratories

Go to company listing